








CORRECTION OPEN



# Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma

Keiji Kurata , Anna James-Bott , Mark A. Tye, Leona Yamamoto, Mehmet K. Samur , Yu-Tzu Tai , James Dunford , Catrine Johansson, Filiz Senbabaoglu, Martin Philpott, Charlotte Palmer, Karthik Ramasamy, Sarah Gooding, Mihaela Smilova, Giorgia Gaeta, Manman Guo, John C. Christianson, N. Connor Payne , Kritika Singh, Kubra Karagoz, Matthew E. Stokes, Maria Ortiz, Patrick Hagner, Anjan Thakurta, Adam Cribbs, Ralph Mazitschek, Teru Hideshima, Kenneth C. Anderson  and Udo Oppermann

© The Author(s) 2023

*Blood Cancer Journal* (2023)13:24; <https://doi.org/10.1038/s41408-023-00793-y>

Correction to: *Blood Cancer Journal* <https://doi.org/10.1038/s41408-023-00787-w>, published online 12 January 2023

In this article, the author name Anna James-Bott was incorrectly written as Anna-James Bott.

The original article has been corrected.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023